<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene A475V literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.A475V</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1 (<a href="https://doi.org/10.1016/j.cell.2020.07.012" class="lit_link">Li et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Resistent to some class 1 (Spike 'up' conformation) antibodies tested.<br/> (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. <br/> (<a href="https://doi.org/10.1101/2020.11.03.367391" class="lit_link">Gaebler et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape) (<a href="https://doi.org/10.1016/j.cell.2020.07.012" class="lit_link">Li et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The engineered mutation cause 10-fold or more increase in the disassociation constant with C102, C105 and C144 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.<br/> (<a href="https://doi.org/10.1038/s41586-020-2852-1" class="lit_link">Barnes et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> COR-101 lost ~50x binding against this isolated mutation.<br/>Estesevimab lost ~8x binding against this isolated mutation. Sotrovimab lost ~30x binding against this isolated mutation.<br/>Tixagevimab lost ~15x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.<br/> (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
